Unidad de Regeneración Neural, Unidad Funcional de Investigación de Enfermedades Crónicas, Instituto de Salud Carlos III (ISCIII), 28220 Majadahonda, Madrid, Spain.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC); CNRS-UMR7104; INSERM-U964, Université de Strasbourg, 1 rue Laurent Fries, 67404, Illkirch, France.
Mol Neurobiol. 2018 Sep;55(9):7107-7117. doi: 10.1007/s12035-018-0914-2. Epub 2018 Jan 30.
Amyloid precursor protein (APP) is a member of the APP family of proteins, and different enzymatic processing leads to the production of several derivatives that are shown to have distinct biological functions. APP is involved in the pathology of Alzheimer's disease (AD), the most common neurodegenerative disorder causing dementia. Furthermore, it is believed that individuals with Down syndrome (DS) have increased APP expression, due to an extra copy of chromosome 21 (Hsa21), that contains the gene for APP. Nevertheless, the physiological function of APP remains unclear. It is known that APP plays an important role in neural growth and maturation during brain development, possibly by influencing proliferation, cell fate specification and neurogenesis of neural stem cells (NSCs). Proteolytic cleavage of APP occurs mainly via two mutually exclusive pathways, the non-amyloidogenic pathway or the amyloidogenic pathway. Other alternative pathways (η-secretase, δ-secretase and meprin pathways) have also been described for the physiological processing of APP. The different metabolites generated from these pathways, including soluble APPα (sAPPα), soluble APPβ (sAPPβ), β-amyloid (Aβ) peptides and the APP intracellular domain (AICD), have different functions determined by their structural differences, equilibrium and concentration with respect to other fragments derived from APP. This review discusses recent observations regarding possible functions of APP and its proteolytic derivatives in the biology and phenotypic specification of NSCs. This can be important for a better understanding of the pathogenesis and the development of future therapeutic applications for AD and/or DS, diseases in which alterations in neurogenesis have been described.
淀粉样前体蛋白 (APP) 是 APP 蛋白家族的成员,不同的酶切处理导致产生几种具有不同生物学功能的衍生物。APP 参与阿尔茨海默病 (AD) 的病理学,AD 是最常见的导致痴呆的神经退行性疾病。此外,人们认为唐氏综合征 (DS) 个体由于 21 号染色体 (Hsa21) 有额外的一份拷贝,其中包含 APP 的基因,因此 APP 表达增加。然而,APP 的生理功能仍不清楚。已知 APP 在大脑发育过程中对神经生长和成熟起着重要作用,可能通过影响神经干细胞 (NSC) 的增殖、细胞命运特化和神经发生。APP 的蛋白水解切割主要通过两种相互排斥的途径发生,即非淀粉样生成途径或淀粉样生成途径。其他替代途径(η-分泌酶、δ-分泌酶和 meprin 途径)也已被描述用于 APP 的生理加工。这些途径产生的不同代谢物,包括可溶性 APPα(sAPPα)、可溶性 APPβ(sAPPβ)、β-淀粉样肽 (Aβ) 和 APP 细胞内结构域 (AICD),具有不同的功能,这取决于它们的结构差异、与其他源自 APP 的片段的平衡和浓度。本综述讨论了 APP 及其蛋白水解衍生物在 NSC 生物学和表型特化中的可能功能的最新观察结果。这对于更好地理解 AD 和/或 DS 的发病机制以及未来针对 AD 和/或 DS 的治疗应用的发展非常重要,在这些疾病中已经描述了神经发生的改变。